IPSEN (OTCMKTS:IPSEY) Receives Average Rating of “Hold” from Brokerages

Shares of IPSEN (OTCMKTS:IPSEY – Get Free Report) have been given an average rating of “Hold” by the seven ratings firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company.

Several analysts have recently weighed in on IPSEY shares. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Zacks Research upgraded IPSEN to a “hold” rating in a report on Friday, May 29th. Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Finally, Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th.

Get IPSEN alerts:

Check Out Our Latest Stock Report on IPSEY

IPSEN Price Performance

IPSEN stock opened at $41.98 on Monday. The firm has a 50-day moving average of $46.11 and a two-hundred day moving average of $46.56. IPSEN has a 1 year low of $32.02 and a 1 year high of $51.10.

About IPSEN

(Get Free Report)

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.

Further Reading

• Five stocks we like better than IPSEN
• Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
• Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
• Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
• Oil May Be Stronger Than It Looks—And Diamondback Is on Sale

Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.